Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect
Open Access
- 16 July 2020
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (8) , 2131-2146
Abstract
Acute graft-versus-host disease causes significant mortality in patients undergoing allogeneic hematopoietic cell transplantation. Immunosuppressive treatment for graft-versus-host disease can impair the beneficial graft-versus-leukemia effect and facilitate malignancy relapse. Therefore, novel approaches that protect and regenerate injured tissues without impeding the donor immune system are needed. Bile acids regulate multiple cellular processes and are in close contact with the intestinal epithelium, a major target of acute graft-versus-host disease. Here, we found that the bile acid pool is reduced following graft-versus-host disease induction in a preclinical model. We evaluated the efficacy of bile acids to protect the intestinal epithelium without reducing anti-tumor immunity. We observed that application of bile acids decreased cytokine-induced cell death in intestinal organoids and cell lines. Systemic prophylactic administration of tauroursodeoxycholic acid, the most potent compound in our in vitro studies, reduced graft-versus-host disease severity in three different murine transplantation models. This effect was mediated by decreased activity of the antigen presentation machinery and subsequent prevention of apoptosis of the intestinal epithelium. Moreover, bile acid administration did not alter the bacterial composition in the intestine suggesting that its effects are cell-specific and independent of the microbiome. Treatment of human and murine leukemic cell lines with tauroursodeoxycholic acid did not interfere with the expression of antigen presentation-related molecules. Systemic T cell expansion and especially their cytotoxic capacity against leukemic cells remained intact. This study establishes a role for bile acids in the prevention of acute graft-versus-host disease without impairing the graft-versus-leukemia effect. In particular, we provide a scientific rationale for the systematic use of tauroursodeoxycholic acid in patients undergoing allogeneic hematopoietic cell transplantation.Keywords
This publication has 50 references indexed in Scilit:
- Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantationJournal of Experimental Medicine, 2012
- Bile acid malabsorption in patients with graft‐versus‐host disease of the gastrointestinal tractBritish Journal of Haematology, 2012
- The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cellsJournal of Experimental Medicine, 2011
- Systemic gut microbial modulation of bile acid metabolism in host tissue compartmentsProceedings of the National Academy of Sciences, 2010
- A Novel Bile Acid-Activated Vitamin D Receptor Signaling in Human HepatocytesMolecular Endocrinology, 2010
- Bile acids: regulation of apoptosis by ursodeoxycholic acidJournal of Lipid Research, 2009
- Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2007
- The Enzymes, Regulation, and Genetics of Bile Acid SynthesisAnnual Review of Biochemistry, 2003
- Identification of membrane-type receptor for bile acids (M-BAR)Biochemical and Biophysical Research Communications, 2002
- Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formationCell Death & Differentiation, 1999